XSTEM
Knee Osteoarthritis
Key Facts
About Xintela
Xintela AB is a biomedical company leveraging its unique integrin platform to address high unmet needs in cartilage damage and aggressive cancers. Founded in 2013 and based in Lund, Sweden, its strategy centers on developing a dual pipeline: XSTEM, an α10β1-selected mesenchymal stem cell therapy for osteoarthritis, and targeted oncology programs against the αvβ3 integrin. As a publicly traded entity on Nasdaq First North, Xintela is progressing its lead candidate through clinical validation while exploring strategic partnerships to accelerate development.
View full company profileAbout Xintela
Xintela AB is a biomedical company leveraging its unique integrin platform to address high unmet needs in cartilage damage and aggressive cancers. Founded in 2013 and based in Lund, Sweden, its strategy centers on developing a dual pipeline: XSTEM, an α10β1-selected mesenchymal stem cell therapy for osteoarthritis, and targeted oncology programs against the αvβ3 integrin. As a publicly traded entity on Nasdaq First North, Xintela is progressing its lead candidate through clinical validation while exploring strategic partnerships to accelerate development.
View full company profileTherapeutic Areas
Other Knee Osteoarthritis Drugs
| Drug | Company | Phase |
|---|---|---|
| Progenza | Cambium Bio | Phase 1/2a |
| MAG200 | Magellan | Phase 3 |
| MUTI™ Knee Replacement | Meril | Commercial |
| DUROLANE | Bioventus | Commercial |
| Stempeucel® | Stempeutics Research | Commercial |
| Lipogems System for Knee Osteoarthritis | Lipogems International | Phase 3 |
| Signature Cord Prime™ | Arugula Sciences | Phase 1 |
| Knee Osteoarthritis Study | Arizona Research Center | Not Specified |
| 4P004 | 4Moving Biotech | Phase 2a |
| Lorecivivint (inferred) | Biosplice Therapeutics | Phase 3 |
| Regenerative Cell Therapy for Osteoarthritis | InGeneron | Phase 3 |
| ArthroCart | Arthro Biotech | Preclinical |